PALO ALTO, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced a publication on GLOPERBA® dosing adjustments in peer-review journal. GLOPERBA® is the first and only liquid oral version of the anti-gout medicine colchici ...

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2025 Scilex Holding Company For the transition period from to Commission File Number 001-39852 (Exact Name of Registrant as Specified in Its Charter) Delaware 92-1062542 (State or Other Jurisdiction of Incor ...

PALO ALTO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that it has received notification from The Nasdaq Stock Market LLC that the Company has regained compliance with the minimum closing bid price requirement ...

Gloperba® is the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.Pericarditis is an inflammation of the pericardium, the sac-like membrane that surrounds and protects the heart. It occurs when the pericardium becomes irritated or infected, leading to swelling and pain. PALO ALTO, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating compan ...

Core Viewpoint - Scilex Holding Company will implement a reverse stock split at a ratio of 1-for-35 effective April 15, 2025, to comply with Nasdaq's minimum bid price requirement of $1.00 per share [1][2]. Company Overview - Scilex is focused on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain, as well as treatments for neurodegenerative and cardiometabolic diseases through a proposed joint venture with IPMC Company [1][8][9]. - The company’s commercial products include ZTlido®, ELYXYB®, and Gloperba®, targeting high unmet needs in pain management [9][10]. Reverse Stock Split Details - The reverse stock split will reduce the number of outstanding shares from approximately 243 million to about 6.9 million [4]. - The split will not affect the authorized number of shares, and stockholders will receive cash payments for any fractional shares [3][5]. - The reverse stock split was approved by stockholders on March 19, 2025, with the board of directors selecting the 1-for-35 ratio on April 3, 2025 [5]. Trading Information - Post-split, Scilex's common stock will continue trading on The Nasdaq Capital Market under the symbol "SCLX" with a new CUSIP number [2]. - Continental Stock Transfer & Trust Company will manage the exchange process for stockholders [6].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39852 Scilex Holding Company (Exact Name of Registrant as Specified in Its Charter) Delaware 92-1062542 (State or Other Jurisdiction of Incorporat ...

Core Viewpoint - Scilex Holding Company is actively pursuing an appeal against a lower court decision that ruled in favor of Aveva Drug Delivery Systems, asserting that Aveva infringes on Scilex's ZTlido patents [1][3][4] Company Overview - Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for both acute and chronic pain [6][10] - The company has a portfolio that includes ZTlido, ELYXYB, and Gloperba, targeting high unmet medical needs in pain management [6][10] Legal Proceedings - In May 2022, Scilex was notified of Aveva's submission of an Abbreviated New Drug Application (ANDA) that may infringe on Scilex's ZTlido patents, leading to a patent infringement lawsuit filed in June 2022 [2] - The U.S. District Court ruled in July 2024 that Aveva's proposed product did not infringe Scilex's patents, prompting Scilex to appeal the decision [3][4] Intellectual Property - Scilex maintains confidence in the strength and validity of its ZTlido intellectual property and believes that Aveva is infringing on its patents [4] - The company is pursuing additional patents for follow-on programs to further protect its intellectual property portfolio [4]

Core Viewpoint - Scilex Holding Company announced the extension of the lock-up period for its Dividend Stock until April 14, 2025, as approved by the U.S. Bankruptcy Court for the Southern District of Texas, affecting shares previously distributed by Sorrento Therapeutics [1][5]. Company Overview - Scilex Holding Company is focused on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain, and is also pursuing a joint venture with IPMC Company in neurodegenerative and cardiometabolic diseases [4][8]. - The company targets high unmet needs in the market with non-opioid therapies and aims to improve patient outcomes [4]. Commercial Products - Scilex's commercial products include: - ZTlido® (lidocaine topical system) 1.8%, approved for neuropathic pain relief [4]. - ELYXYB®, an FDA-approved oral solution for acute migraine treatment [4]. - Gloperba®, the first liquid oral version of colchicine for gout flare prophylaxis [4]. Product Candidates - Scilex has three product candidates in development: - SP-102 (SEMDEXA™), a viscous gel for epidural injections to treat sciatica, which has completed Phase 3 studies [5][6]. - SP-103, a next-generation lidocaine topical system for acute pain, recently completed Phase 2 trials [6]. - SP-104, a low-dose naltrexone hydrochloride for fibromyalgia treatment [6]. Regulatory Status - SP-102 has received Fast Track status from the FDA, indicating its potential for expedited development [6]. - SP-103 has also been granted Fast Track status for low back pain [6]. Market Position - Scilex is headquartered in Palo Alto, California, and is positioned as a clinical late-stage specialty pharmaceutical company focusing on non-opioid pain therapies [7][8].

Core Viewpoint - Scilex Holding Company has announced the acknowledgment of its Supplemental New Drug Application (SNDA) for ELYXYB by the U.S. FDA, targeting acute pain indications, which is a significant step in expanding its non-opioid pain management portfolio [1]. Company Overview - Scilex Holding Company is focused on acquiring, developing, and commercializing non-opioid pain management products for both acute and chronic pain [3][4]. - The company is headquartered in Palo Alto, California [5]. Product Portfolio - Scilex's commercial products include: - ZTlido (lidocaine topical system) 1.8%, approved for neuropathic pain relief associated with postherpetic neuralgia [3]. - ELYXYB, the only FDA-approved ready-to-use oral solution for acute migraine treatment in adults [3]. - Gloperba, the first liquid oral version of colchicine for the prophylaxis of painful gout flares [3]. - The company has three product candidates in development: - SP-102 (SEMDEXA™), a viscous gel for epidural injections to treat lumbosacral radicular pain, which has completed a Phase 3 study [4]. - SP-103, a next-generation lidocaine topical system for acute pain, recently completed a Phase 2 trial [4]. - SP-104, a low-dose naltrexone hydrochloride for fibromyalgia treatment [4]. Strategic Initiatives - Scilex is forming a proposed joint venture with IPMC Company to develop treatments for neurodegenerative and cardiometabolic diseases, indicating a strategic expansion beyond pain management [1][3].

Core Viewpoint - Scilex Holding Company has regained compliance with Nasdaq Listing Rule 5250(c)(1) following the filing of its Quarterly Report for the quarter ended September 30, 2024, and continues to focus on non-opioid pain management products and potential joint ventures for treating neurodegenerative and cardiometabolic diseases [1]. Company Overview - Scilex Holding Company is based in Palo Alto, California, and specializes in acquiring, developing, and commercializing non-opioid pain management products for both acute and chronic pain [3][5]. - The company aims to address high unmet needs in the market with non-opioid therapies and is dedicated to improving patient outcomes [3]. Product Portfolio - Scilex's commercial products include: - ZTlido (lidocaine topical system) 1.8%, approved by the FDA for neuropathic pain relief associated with postherpetic neuralgia [3]. - ELYXYB, the only FDA-approved ready-to-use oral solution for acute migraine treatment in adults [3]. - Gloperba, the first liquid oral version of colchicine for the prophylaxis of painful gout flares in adults [3]. Product Candidates - Scilex has three product candidates in development: - SP-102 (SEMDEXA™), a viscous gel formulation for epidural injections to treat lumbosacral radicular pain, which has completed a Phase 3 study and received Fast Track status from the FDA [4]. - SP-103, a next-generation lidocaine topical system for acute pain, which has recently completed a Phase 2 trial and also received Fast Track status from the FDA [4]. - SP-104, a low-dose naltrexone hydrochloride delayed-release capsule for fibromyalgia treatment [4]. Joint Venture - The company is in the process of forming a joint venture with IPMC Company, which aims to expand its focus to neurodegenerative and cardiometabolic diseases [1][8].